Pfizer Inc. will inject $95m into Valneva SE to consolidate the firms’ existing Lyme disease partnership, boosting the French company after a recent spate of commercial setbacks regarding its COVID-19 program.
The investment made under the equity subscription agreement represents 8.1% of Valneva’s share capital at a price of €9.49 per...